Below are the most recent publications written about "Rabies virus" by people in Profiles.
-
Ben Hamed S, Myers JF, Chandwani A, Wirblich C, Kurup D, Paran N, Schnell MJ. Toward the Development of a Pan-Lyssavirus Vaccine. Viruses. 2024 Jul 10; 16(7).
-
Kurup D, Wirblich C, Zabihi Diba L, Lambert R, Watson M, Shaikh N, Ramage H, Solomides C, Schnell MJ. A Single Dose of the Deactivated Rabies-Virus Vectored COVID-19 Vaccine, CORAVAX, Is Highly Efficacious and Alleviates Lung Inflammation in the Hamster Model. Viruses. 2022 May 24; 14(6).
-
Kurup D, Malherbe DC, Wirblich C, Lambert R, Ronk AJ, Zabihi Diba L, Bukreyev A, Schnell MJ. Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model. PLoS Pathog. 2021 03; 17(3):e1009383.
-
Beier KT, Kim CK, Hoerbelt P, Hung LW, Heifets BD, DeLoach KE, Mosca TJ, Neuner S, Deisseroth K, Luo L, Malenka RC. Rabies screen reveals GPe control of cocaine-triggered plasticity. Nature. 2017 09 21; 549(7672):345-350.
-
da Fontoura Budaszewski R, Hudacek A, Sawatsky B, Krämer B, Yin X, Schnell MJ, von Messling V. Inactivated Recombinant Rabies Viruses Displaying Canine Distemper Virus Glycoproteins Induce Protective Immunity against Both Pathogens. J Virol. 2017 Apr 15; 91(8).
-
Gnanadurai CW, Yang Y, Huang Y, Li Z, Leyson CM, Cooper TL, Platt SR, Harvey SB, Hooper DC, Faber M, Fu ZF. Differential Host Immune Responses after Infection with Wild-Type or Lab-Attenuated Rabies Viruses in Dogs. PLoS Negl Trop Dis. 2015; 9(8):e0004023.
-
Wanjalla CN, Goldstein EF, Wirblich C, Schnell MJ. A role for granulocyte-macrophage colony-stimulating factor in the regulation of CD8(+) T cell responses to rabies virus. Virology. 2012 May 10; 426(2):120-33.
-
Li J, Ertel A, Portocarrero C, Barkhouse DA, Dietzschold B, Hooper DC, Faber M. Postexposure treatment with the live-attenuated rabies virus (RV) vaccine TriGAS triggers the clearance of wild-type RV from the Central Nervous System (CNS) through the rapid induction of genes relevant to adaptive immunity in CNS tissues. J Virol. 2012 Mar; 86(6):3200-10.
-
Blaney JE, Wirblich C, Papaneri AB, Johnson RF, Myers CJ, Juelich TL, Holbrook MR, Freiberg AN, Bernbaum JG, Jahrling PB, Paragas J, Schnell MJ. Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J Virol. 2011 Oct; 85(20):10605-16.
-
Mustafa W, Al-Saleem FH, Nasser Z, Olson RM, Mattis JA, Simpson LL, Schnell MJ. Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge. Vaccine. 2011 Jun 20; 29(28):4638-45.